Pefcalcitol

Summary

Pefcalcitol (CHEMBL3989862) is a phase-3 clinical-stage small molecule; indicated across 1 condition including psoriasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 9
• Chemistry: 519.5 Da · C26H34F5NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989862
Name	Pefcalcitol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16122802
Molecular formula	C26H34F5NO4
Molecular weight	519.5
InChIKey	SVCSMAZYWOQCBW-NVJMFHFGSA-N

SMILES: C[C@@H](C1=CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCC(=O)NCC(C(F)(F)F)(F)F

IUPAC name: 2-[(1S)-1-[(3aS,4E,7aS)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-1-yl]ethoxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide

Also known as: M-5181, M-518101, M5181, M518101, Pefcalcitol, PEFCALCITOL

Patent coverage: 73 distinct patent families (208 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	3	MONDO:0005083	EFO:0000676

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01873677	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
NCT01878461	PHASE3	COMPLETED	Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
NCT01908595	PHASE3	COMPLETED	Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
NCT01989429	PHASE3	COMPLETED	Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
NCT00884169	PHASE2	COMPLETED	Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients
NCT01301157	PHASE2	COMPLETED	Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
NCT01844973	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients
NCT02227069	PHASE1	COMPLETED	Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers
NCT02256930	PHASE1	COMPLETED	Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).